Accessibility Menu
Oncotelic Therapeutics logo

Oncotelic Therapeutics(OTC) OTLC

Market Cap$18.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-62%
5 Year-76%
1 Year-18%
1 Month-6%
$0.04
+19.43%
+0.01Today
Oncotelic Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.042026-07-27
Oncotelic Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.65%USD 0.042026-07-20
1 month-6.18%USD 0.042026-06-26
3 month+15.97%USD 0.042026-04-28
Year to date-46.75%USD 0.082025-12-31
1 year-18.14%USD 0.052025-07-25
3 year+83.52%USD 0.022023-07-28
5 year-75.99%USD 0.172021-07-28
Since inception-62.05%USD 0.112019-04-23

Oncotelic Therapeutics Financials at a Glance

Market Cap

$18.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$247.38M

EPS (TTM)

$0.56

P/E Ratio

0.07

Dividend

$0.00

Beta (Volatility)

0.17 (Low)

Price

$0.04

Volume

458,456

Open

$0.04

Previous Close

$0.04

Daily Range

$0.04 - $0.04

52-Week Range

$0.02 - $0.11

Estimated Earnings Date

Aug 24, 2026

OTLC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Oncotelic Therapeutics

Oncotelic develops medicines for hard-to-treat cancers and rare diseases. Its main drugs aim to help patients with few treatment options. The company focuses on therapies for both people and animals.

Lab Bench to Bedside: What Oncotelic Sells

  • OT-101 (Lead Drug): Experimental treatment for pancreatic cancer, brain cancer, and some viral diseases; 0% of revenue.
  • OXi4503: Drug candidate for blood cancers like acute myeloid leukemia; 0% of revenue.
  • CA4P: Investigational therapy for advanced metastatic melanoma; 0% of revenue.
  • Apomorphine: Under development for Parkinson’s disease and sexual dysfunction; 0% of revenue.
  • Pet2DAO: Animal health initiative using digital tokens; 0% of revenue.
  • EdgePoint AI: Artificial intelligence tools for drug development; 0% of revenue.

Growth and Expansion: The Oncotelic Timeline

  • Formed joint venture with GMP Biotechnology Limited in 2022 for drug development and manufacturing.
  • Launched in-house manufacturing facility in San Diego in late 2024.
  • Partnered with Shanghai Medicilon in early 2025 to speed up new drug applications.
  • Continued expansion into animal health and AI-driven drug development in 2025.

What Makes Oncotelic Stand Out

Oncotelic owns a manufacturing facility, giving it control over drug production. Its joint ventures and partnerships help spread risk and speed up development. The company uses both traditional and digital approaches, including artificial intelligence and blockchain, to broaden its reach.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, unchanged from Q2 2024 and Q2 2023.
  • Net income was $277,856 in Q2 2025, up from a $209,837 loss in Q2 2024.
  • Operating expenses decreased by 31.7% to $65,969 in Q2 2025 from Q2 2024.
  • Cash was $108,022 as of June 30, 2025, with negative working capital of $19.1 million.

Bottom Line

Oncotelic remains a clinical-stage company with no product sales and ongoing financial challenges. Its value lies in its drug pipeline, partnerships, and manufacturing capabilities.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

56

CEO

Vuong Trieu, PhD

Website

www.oncotelic.com

Headquarters

Agoura Hills, CA 91301, US

OTLC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

0.00%

Return on Capital

-0.00%

Return on Assets

0.00%

Earnings Yield

14.29%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$18.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

443.62M

Volume

458.46K

Avg. Volume

305.04K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$4.94M

EBITDA

$343.63B

Operating Cash Flow

-$1.56M

Capital Expenditure

-$5.00

Free Cash Flow

-$1.56M

Cash & ST Invst.

$63.61B

Total Debt

$16.79T

Oncotelic Therapeutics Performance Analysis

Oncotelic Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 70,000N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Oncotelic Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Oncotelic Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.01N/A
20232023-12-31USD -0.02N/A
20242024-12-31USD -0.01-44.0%
20252025-12-31USD 0.59N/A
Oncotelic Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30185.7%
Q32025-09-30-516.7%
Q42025-12-3123700.0%
Q12026-03-31-100.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$18.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$712.35K

N/A

Employees

26

N/A

Net Income

-$2.19M

-634.4%

EBITDA

$145.58B

+90723517.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$63.61B

+80347998.5%

Total Debt

$16.79T

+126383766.4%

Accounts Receivable

$2.06K

-89.2%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$16.79T

+126383766.4%

Return on Assets

0.00%

N/A

Return on Invested Capital

-0.00%

N/A

Free Cash Flow

-$342.24K

-105.0%

Operating Cash Flow

-$342.24K

-105.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZIVOZIVO Bioscience, Inc.
$5.00+0.00%
CXXIFC21 Investments Inc.
$0.21+3.47%
RLFTFMindMaze Therapeutics Holding S.A.
$0.22+12.00%
PSYBFPsyBio Therapeutics Corp
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.23+0.02%
AALAmerican Airlines Group
$14.95+0.03%

Questions About OTLC

What is the current price of Oncotelic Therapeutics?

Oncotelic Therapeutics is trading at $0.04 per share.

What is the 52-week range for Oncotelic Therapeutics?

Over the past 52 weeks, Oncotelic Therapeutics has traded between $0.02 and $0.11.

How much debt does Oncotelic Therapeutics have?

As of the most recent reporting period, Oncotelic Therapeutics reported total debt of $14.75M.

How much cash does Oncotelic Therapeutics have on hand?

Oncotelic Therapeutics reported $83.61K in cash and cash equivalents in its most recent financial results.

What is Oncotelic Therapeutics’s dividend yield?

Oncotelic Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services